{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:39:34Z","timestamp":1793385574341,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.chest.2024.09.049","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T19:38:33Z","timestamp":1733168313000},"page":"1346-1355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-8371","authenticated-orcid":false,"given":"Bartolome R.","family":"Celli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8918-7075","authenticated-orcid":false,"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3087-9530","authenticated-orcid":false,"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-1689","authenticated-orcid":false,"given":"Leonardo","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-3182","authenticated-orcid":false,"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Djandji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.chest.2024.09.049_bib1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra1900500","article-title":"Update on clinical aspects of chronic obstructive pulmonary disease","volume":"381","author":"Celli","year":"2019","journal-title":"N Engl J Med"},{"issue":"10356","key":"10.1016\/j.chest.2024.09.049_bib2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(22)01273-9","article-title":"Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission","volume":"400","author":"Stolz","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.chest.2024.09.049_bib3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","article-title":"An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal","volume":"204","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2024.09.049_bib4","doi-asserted-by":"crossref","first-page":"1602265","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/resp.14041","article-title":"Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact","volume":"26","author":"MacLeod","year":"2021","journal-title":"Respirology"},{"issue":"11","key":"10.1016\/j.chest.2024.09.049_bib6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa","year":"2012","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.chest.2024.09.049_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","volume":"18","author":"Barnes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.chest.2024.09.049_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/COPD.S152291","article-title":"Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease","volume":"13","author":"Tashkin","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.chest.2024.09.049_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood eosinophils and chronic obstructive pulmonary disease: a Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review","volume":"206","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.chest.2024.09.049_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2024.09.049_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/15412555.2019.1708296","article-title":"Effects of lung function-related genes and TSLP on COPD phenotypes","volume":"17","author":"Yamada","year":"2020","journal-title":"COPD"},{"issue":"9","key":"10.1016\/j.chest.2024.09.049_bib12","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202003-0625ST","article-title":"Pharmacologic management of chronic obstructive pulmonary disease. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Nici","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2024.09.049_bib14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"10082","key":"10.1016\/j.chest.2024.09.049_bib15","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.chest.2024.09.049_bib16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2147\/COPD.S175706","article-title":"Personalized medicine for patients with COPD: Where are we?","volume":"14","author":"Franssen","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.chest.2024.09.049_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17476348.2020.1804364","article-title":"Endo-phenotyping of COPD patients","volume":"15","author":"Barnes","year":"2021","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pulmoe.2019.10.006","article-title":"Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art","volume":"26","author":"Corlateanu","year":"2020","journal-title":"Pulmonology"},{"issue":"7","key":"10.1016\/j.chest.2024.09.049_bib19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"issue":"13","key":"10.1016\/j.chest.2024.09.049_bib20","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMra1900475","article-title":"Update on the pathogenesis of chronic obstructive pulmonary disease","volume":"381","author":"Agust\u00ed","year":"2019","journal-title":"N Engl J Med"},{"issue":"5 pt 1","key":"10.1016\/j.chest.2024.09.049_bib21","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1164\/ajrccm.158.5.9804028","article-title":"Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis","volume":"158","author":"Pizzichini","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib23","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/all.14661","article-title":"Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Higham","year":"2021","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib24","doi-asserted-by":"crossref","first-page":"1900651","DOI":"10.1183\/13993003.00651-2019","article-title":"Airway inflammation in COPD: progress to precision medicine","volume":"54","author":"Brightling","year":"2019","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib26","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.chest.2024.09.049_bib27","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.202009-3448OC","article-title":"Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis","volume":"203","author":"Wang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2024.09.049_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00150-2024","article-title":"Type 2 airway inflammation in COPD","volume":"63","author":"Polverino","year":"2024","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.09.049_bib29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1164\/rccm.200203-183OC","article-title":"Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease","volume":"167","author":"Fabbri","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2024.09.049_bib30","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jaci.2010.01.003","article-title":"Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up","volume":"125","author":"Contoli","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"10.1016\/j.chest.2024.09.049_bib31","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.chest.2024.09.049_bib32","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.202301-0149OC","article-title":"Eosinophil subtypes in adults with asthma and adults with chronic obstructive pulmonary disease","volume":"208","author":"L\u00f3pez","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1165\/rcmb.2009-0117OC","article-title":"Involvement of IL-13 in tobacco smoke-induced changes in the structure and function of rat intrapulmonary airways","volume":"43","author":"Cooper","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.chest.2024.09.049_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jaci.2017.04.027","article-title":"Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts","volume":"140","author":"Kolsum","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.chest.2024.09.049_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/rccm.201408-1458OC","article-title":"Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease","volume":"191","author":"Christenson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/all.14016","article-title":"Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma","volume":"75","author":"George","year":"2020","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.chest.2024.09.049_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib39","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","article-title":"Interleukin-33 in tissue homeostasis, injury, and inflammation","volume":"42","author":"Molofsky","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.chest.2024.09.049_bib40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol Rev"},{"issue":"10","key":"10.1016\/j.chest.2024.09.049_bib41","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation","volume":"183","author":"Kurowska-Stolarska","year":"2009","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib42","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jaci.2014.05.011","article-title":"IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice","volume":"134","author":"Li","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib43","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jaci.2008.04.005","article-title":"A novel IL-1 family cytokine, IL-33, potently activates human eosinophils","volume":"121","author":"Cherry","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nm.2156","article-title":"Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection","volume":"16","author":"Alves-Filho","year":"2010","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.chest.2024.09.049_bib45","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1172\/JCI65570","article-title":"Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease","volume":"123","author":"Byers","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.chest.2024.09.049_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/imm.12020","article-title":"Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice","volume":"138","author":"Qiu","year":"2013","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.chest.2024.09.049_bib47","doi-asserted-by":"crossref","first-page":"L619","DOI":"10.1152\/ajplung.00305.2014","article-title":"Increased IL-33 expression in chronic obstructive pulmonary disease","volume":"308","author":"Xia","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"5","key":"10.1016\/j.chest.2024.09.049_bib48","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.4049\/jimmunol.1000252","article-title":"Thymic stromal lymphopoietin in cigarette smoke-exposed human airway smooth muscle","volume":"185","author":"Smelter","year":"2010","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib49","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jaci.2018.01.051","article-title":"Viral induced overproduction of epithelial TSLP: Role in exacerbations of asthma and COPD?","volume":"142","author":"Uller","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.chest.2024.09.049_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.arbres.2012.04.001","article-title":"Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery","volume":"48","author":"Miravitlles","year":"2012","journal-title":"Arch Bronconeumol"},{"issue":"8","key":"10.1016\/j.chest.2024.09.049_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.arbres.2013.12.013","article-title":"Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke","volume":"50","author":"Golpe","year":"2014","journal-title":"Arch Bronconeumol"},{"issue":"5","key":"10.1016\/j.chest.2024.09.049_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.arbr.2017.10.025","article-title":"Smoking in COPD patients: A new clinical phenotype?","volume":"54","author":"Carri\u00f3n Valero","year":"2018","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"9","key":"10.1016\/j.chest.2024.09.049_bib53","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1164\/rccm.201404-0720OC","article-title":"FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure","volume":"190","author":"Ram\u00edrez-Venegas","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.chest.2024.09.049_bib54","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.1994.03520190043033","article-title":"Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study","volume":"272","author":"Anthonisen","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.chest.2024.09.049_bib55","first-page":"1","article-title":"Health of former cigarette smokers aged 65 and\u00a0over: United States, 2018","volume":"145","author":"Kramarow","year":"2020","journal-title":"Natl Health Stat Report"},{"issue":"1","key":"10.1016\/j.chest.2024.09.049_bib56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2213-2600(19)30276-0","article-title":"Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study","volume":"8","author":"Oelsner","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ypmed.2008.11.012","article-title":"Associations between health-related quality of life and smoking status among a large sample of U.S. adults","volume":"48","author":"McClave","year":"2009","journal-title":"Prev Med"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib58","first-page":"3","article-title":"Dynamics of smoking cessation and health-related quality of life among Canadians","volume":"24","author":"Shields","year":"2013","journal-title":"Health Rep"},{"issue":"3","key":"10.1016\/j.chest.2024.09.049_bib59","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/ntr\/nts182","article-title":"Smoking status, physical health-related quality of life, and mortality in middle-aged and older women","volume":"15","author":"Holahan","year":"2013","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.chest.2024.09.049_bib60","doi-asserted-by":"crossref","first-page":"g1151","DOI":"10.1136\/bmj.g1151","article-title":"Change in mental health after smoking cessation: systematic review and meta-analysis [published correction appears in BMJ. 2014;348:g2216]","volume":"348","author":"Taylor","year":"2014","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.chest.2024.09.049_bib61","first-page":"289","article-title":"Employment and activity limitations among adults with chronic obstructive pulmonary disease \u2014 United States, 2013","volume":"64","author":"Wheaton","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.chest.2024.09.049_bib62","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01393-2017","article-title":"Cigarette smoking and response to inhaled corticosteroids in COPD","volume":"51","author":"Bhatt","year":"2018","journal-title":"Eur Respir J"},{"issue":"18","key":"10.1016\/j.chest.2024.09.049_bib63","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chest.2024.09.049_bib64","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD [published correction appears in N Engl J Med. 2012;366:1356]","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2024.09.049_bib65","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1038\/ncomms9327","article-title":"Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.chest.2024.09.049_bib67","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 Antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease","volume":"191","author":"Rennard","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2024.09.049_bib68","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.chest.2024.09.049_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaip.2023.11.007","article-title":"Efficacy and safety of biologics for oral corticosteroid-dependent asthma: a systematic review and network meta-analysis","volume":"12","author":"Phinyo","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.chest.2024.09.049_bib77","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2024.09.049_bib74","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2024.09.049_bib70","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11739-020-02612-9","article-title":"Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease","volume":"16","author":"Waeijen-Smit","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"6","key":"10.1016\/j.chest.2024.09.049_bib78","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.chest.2018.07.005","article-title":"Pharmacological therapy of COPD: reasons for optimism","volume":"154","author":"Celli","year":"2018","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2024.09.049_bib73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224056022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224056022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:05:03Z","timestamp":1762124703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224056022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0012369224056022"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.09.049","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.09.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}